Cardiovascular biomarker market could hit $7.2B by 2018

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

The global market of diagnostic biomarkers for the detection of cardiovascular disease is expected to soar steadily at a compound annual growth rate (CAGR) of 12.8 percent between 2013 and 2018.

The March report titled “Cardiac Biomarkers: Technologies and Global Markets” was developed by BCC Research and announced April 10.

According to the report, the worldwide market for cardiac biomarkers was valued around $4 billion last year, up from an estimated $3.1 billion in 2012.

The report notes a trend during this five-year period in biomarkers for heart failure, especially ST2 and galectin-3, and others for the detection of stroke, including GFAP and S100-beta.

The biomarkers driving the market were listed as B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), choline, creatine kinase MB (CK-MB), D-dimer, glial fibrillary acidic protein (GFAP), heart fatty acid binding protein (H-FABP), ischemia-modified albumin (IMA), myeloperoxidase (MPO), myoglobin, soluble fragment CD40 ligand (sCD40L), and troponin I (cTnI) and troponin T (cTnT).

Kathy Mahdoubi

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.